fashion -WSS

fashion

author：knowledge 2025-09-28 02:27:09 - browse：9

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Too many hospitalized Covid

WSS

Latigo launches with $135 million for Vertex

STAT Summit: How researchers deal with rejection

Doctors on social media are being harassed and cyberbullied

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Readout LOUD podcast: Live from the 2023 STAT Summit

CZI to create biohub to build anti

knowledge

fashion

Wikipedia

Drug repurposing or repositioning? The language matters

Congress considering partial increase for doctor pay in Medicare

The high cost of giving birth even with insurance

Roivant's CEO is a star, but biotech's black hole persists

Peter Hotez and the public health issue of online harassment

Having children helps parents live longer, especially after age 80

How to save PrEP access — and even expand it

Bernie Sanders gets little from pharma CEOs on drug prices

Peter Hotez and the public health issue of online harassment

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

leisure time

ADCs take center stage as promising cancer treatments

Why a market frenzy over new weight loss drugs defies logic

J&J lung cancer data amount to new salvo against AstraZeneca

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Report cites 'urgent' need to recruit more diverse clinical trial participants

CZI to create biohub to build anti

explore

hotspot

knowledge

Wikipedia